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Meryl Brod1*† and Hein Fennema2†Abstract
Background: Controlled Ovarian Stimulation (COS) is the first step for in vitro fertilization (IVF) treatment, a
treatment often described and experienced as stressful to patients and their partners. COS also requires concerted
efforts by the patients in administering medication and general compliance to treatment protocols. Little is known
about the impacts on patients that may be specific to this important first step in treatment. The absence of a
conceptually sound and well-validated measure assessing patient experience and functioning during ovarian
stimulation has been an obstacle to understanding the impacts of ovarian stimulation on women pursuing IVF. To
address this gap, the Controlled Ovarian Stimulation Impact Measure (COSI) was developed based upon accepted
methods for designing patient reported outcome (PRO) measures. The purpose of this study was to
psychometrically validate the COSI.
Methods: 267 patients from three countries (Ireland, United Kingdom, United States) were administered the COSI.
Psychometric validation was conducted according to an a priori statistical analysis plan.
Results: The final 28-item COSI was found to have robust scale structure with four domains: Interference in Daily
Life (Work and Home), Injection Burden, Psychological Health and Compliance Worry. Internal consistency of all
domains was adequate (between 0.80 to 0.87) as was test-retest reliability (between 0.72-0.87). All a-priori
hypotheses for convergent and known-groups validity tests were met.
Conclusions: There is a measurable impact of COS on patient functioning and well-being. The COSI is a
well-developed and validated PRO measure of this impact. Future work should include examination of
responsiveness and confirmation of concepts in non-western countries.
Keywords: Controlled ovarian stimulation, Validation, Controlled ovarian stimulation impact measure, Quality of lifeBackground
In vitro fertilization (IVF) has been documented as a po-
tentially difficult treatment process with impacts on pa-
tients and their partners. Researchers have observed
increased anxiety levels in patients at several junctures
within the IVF cycle [1]. These points of increased impact
include prior to the beginning of a cycle [2-6]; before oo-
cyte retrieval and prior to embryo transfer [7-10]; before
administering a pregnancy test [9-11]; waiting for the re-
sults of IVF [9,11]; and following an unsuccessful IVF* Correspondence: mbrod@thebrodgroup.net
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distribution, and reproduction in any medium[2-4,12-14]. Furthermore, there is some evidence that
infertility-related stress, anxiety, and depressive symptoms
may negatively affect infertility treatment outcome [15-19],
however there are conflicting results in this research area
[20]. Despite these reports, little attention has been given to
discrete procedures within the IVF treatment process and
impacts on patients that may be specific to these proce-
dures and treatment phases.
IVF treatment involves five phases: (i) ovarian stimula-
tion; (ii) oocyte retrieval; (iii) fertilization followed by em-
bryo culture; (iv) embryo transfer; and (v) the luteal phase.
Controlled Ovarian Stimulation (COS) is the first step in
IVF treatment. COS also requires concerted efforts by the
patients, and perhaps their partners, in administeringentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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A recent study by the first author, consisting of patient
interviews and focus groups in three countries, revealed
that COS can place significant burdens on patients as a
discrete phase in the IVF process, impacts so great that they
could be recalled up to a year after the COS [21]. Further-
more, the impacts were sustained regardless of the outcome
of IVF, whether or not pregnancy was achieved [21]. This
study demonstrated that the frequent injection and moni-
toring associated with COS contributed to the burden
specific to COS, impacting psychological and daily func-
tioning. Despite this one study, little is known about the
specific extent and burden of COS impacts on women pur-
suing IVF as currently the only validated measure of the
impact of fertility problems on quality of life is the
FertiQoL. However, the FertiQoL does not specifically focus
on the impact of COS and no COS treatment specific
patient reported outcome measure (PRO) of the impacts
has been available.
To address this gap, the Controlled Ovarian Stimula-
tion Impact Measure (COSI) was developed in order to
provide a way of assessing and understanding the im-
pacts of controlled ovarian stimulation on functioning
and well-being for patients undergoing IVF. The devel-
opment process followed accepted principles of measure
development for patient reported outcomes [22]. To en-
sure content validity of the COSI, the concept elicitation
phase included literature review, expert interviews, and
direct input from 47 women who have experienced COS
[21]. Based on these findings, a conceptual model was
developed and 46 possible items were generated from
the model using the patient/participant voices. The pur-
pose of this study was to psychometrically validate the
COSI by developing a formal measurement model that
identifies domains and subscales from the initial item
pool, and explore the reliability and validity of the COSI
using a pre-specified analysis plan [23,24].
Methods
Subjects
This multicenter, non-interventional study was conduc-
ted in 10 clinics located in Ireland (1 site), the United
Kingdom (3 sites), and the United States (6 sites). Women
receiving Controlled Ovarian Stimulation (COS) for IVF
and/or intracytoplasmic sperm injection (ICSI) treatment
were enrolled in the study. Ethics approval was received
in all 3 countries (US: Independent Review Consulting #
3239–001, UK: reference #07/H1306/161, Ireland:
Rotunda Hospital, no number provided).
Eligibility criteria included women who were scheduled
to undergo COS for IVF/ICSI within the next month, were
between the ages of 18–39 years of age at the time of
signing informed consent, able to read and speak English,
and willing and able to sign informed consent. Womenknown to have either psychiatric illness or alcohol/drug
abuse within the previous 12 months were not eligible to
participate.
All eligible women who had appointments to proceed
to human chorionic gonadotrophin (hCG) administra-
tion (the final COS injection) as part of their treatment
were consecutively asked to participate in the study.
Study participants who did not proceed to hCG adminis-
tration and had a cancelled cycle were not allowed to
continue in the study. These participants were dropped
from the study and replaced by another patient.
The routine medical procedures and/or medications of
the participants were not changed in any way by partici-
pation in the study. This study was reviewed and ap-
proved by an Institutional Review Board and all patients
signed an informed consent.
Procedure
Participants were asked to complete a battery of question-
naires at the day of hCG or the day after. Women were
given the battery to take home with them at their final
monitoring visit prior to hCG administration, when the
decision was made to proceed to hCG injection. If the de-
cision to proceed to hCG was expected to be made when
the woman was not in the clinic, the battery was given at
the participant’s monitoring visit on stimulation day 7 or 8
of their COS treatment. Women were informed that they
should complete all questionnaires in the validation bat-
tery either the day of or the day after their hCG injection,
without interference or discussion from another person,
and return the completed battery to the clinic at the oo-
cyte retrieval appointment.
At the embryo transfer appointment, a subsample of
178 women received the COSI retest with a pre-stamped
pre-addressed envelope. They were instructed to complete
the measure on day 8 following embryo transfer.
Measures
The survey took approximately 35 minutes to complete.
In order to conduct the psychometric analyses required to
validate the measure, additional measures were also in-
cluded in the survey battery along with the COSI. Table 1
presents which measures were employed for each of the
psychometric analyses. These measures include:
Diabetes fear of injecting and self-testing questionnaire (D-
FISQ) - fear of self injecting (FSI) subscale
A 15-item quality-of-life subscale measuring fear of self
injecting in adult diabetics. Subjects rate the items on a
4-point scale as 0 (“almost never”), 1 (“sometimes”), 2
(“often”), or 3 (“almost always”) over the past month. FSI
subscale scores are calculated by summation to detect
and quantify the degree of emotional, cognitive, behav-
ioral and physiological level of fear of self-injecting [25].
Table 1 Hypotheses for the tests of validity
Domain tested Hypotheses
Convergent Validity
Total score There will be a strong correlation with life
satisfaction on the Q-LES-Q.
Psychological Impact Women with greater mental health on the
PGWBI will have lower domain scores.
Interference in Daily
Life
Women who have higher scores on the HFRDIS
will have greater domain scores.
Injection Burden Women with greater scores on the TSQM or the
ITSQ Convenience subscale will have greater
domain scores.
Work Women with greater negative scores on the
Work Productivity Scale (EWPS) will have greater
domain scores and women who self report a
negative work impact will have lower domain
scores.
Compliance Worry Women with greater Compliance Worry will have
greater treatment inconvenience.
Discriminate validity
Total score Greater fear of injection as assessed by the D-
FISQ will be associated with a greater COSI score.
Psychological Impact Women who have more supportive spouses will
have greater domain scores.
Daily Life
Interference
Women who work will have greater domain
scores than women who do not work.
Injection Burden Women who mix their COS medication and/or
who have previous experience with self-injections
will have greater Injection Burden.
Work Women who self-report a supportive work
environment will have lower domain scores.
Compliance Worry Women who feel they were better trained to
administer injections will have less Compliance
Worry.
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LES-Q) (short form)
A 16-item questionnaire assessing the degree of enjoy-
ment and satisfaction experienced in eight areas (physical
health, subjective feelings of well-being, work, household
duties, school, leisure, social relationships, and general life
quality). Each item is rated on a 5-point Likert scale that
indicates the degree of enjoyment or satisfaction achieved
during the past week (1 = “very poor”; 5 = “very good”).
Scores are aggregated, with higher scores indicative of
greater enjoyment or satisfaction in each domain [26].
Endicott work productivity scale (EWPS)
A 25-item questionnaire measuring the degree to
which a medical condition affects subjects’ work func-
tioning. Subjects rate the items on a 5-point Likert
scale measuring frequency from 0 (“never”) to 4 (“al-
most always”) over the past week. Scores are aggre-
gated; the maximum score possible (worst) is 100 and
the best possible score is 0. Total score is based on thedegree to which behaviors and subjective feelings or at-
titudes that are likely to reduce productivity and effi-
ciency in work activities characterize the subject
during the week before evaluation. The number of
hours of work expected, the number worked, and the
reason(s) why the subject worked less than usual are
also collected [27].
Frequency, intensity, and burden of side effects rating
(FIBSER)
A 3-item questionnaire measuring medication side ef-
fect impact over the past week using 3 domains: fre-
quency, intensity, and global burden (degree interfered
with day-to-day functions). Each domain is rated on a
7-point scale (Frequency: ranging from “no side ef-
fects” to “present all of the time”; Intensity: ranging
from “no side effects” to “intolerable”; Burden: ranging
from “no impairment” to “unable to function due to
side effects”). Each specific domain is assessed as a
total value and compared to develop a picture of over-
all effect of medication side effects, e.g., some side ef-
fects may occur infrequently, but be both intense and
very burdensome to the patient or other side effects
may be highly frequent, but be only of modest intensity
and minimal burden [28].
Hot flash related daily interference scale (HFRDIS)
A 10-item questionnaire, adapted so that that it mea-
sured the degree to which ovarian stimulation interferes
with nine daily activities. Subjects rate the degree of
interference with each item during the previous week
using a 0 (“do not interfere”) to 10 (“completely inter-
fere”) scale. A total scale is computed by summing items.
Higher scores indicate higher interference and thus,
greater impact on quality of life [29].
Insulin treatment satisfaction questionnaire: convenience
domain (ITSQ)
A 5-item domain of a 22 item questionnaire assessing
treatment satisfaction for diabetic patients on insulin
over the past month, adapted to assess the impact of the
convenience of ovarian stimulation. All items are rated
on a 7-point Likert scale and scored by transforming all
items to a scale of 0–100 with the higher score (for the
overall score and for each subscale) indicating better
treatment satisfaction. ITSQ subscale scores are calcu-
lated by imputing the missing values based on the mean
of the non-missing items [30].
Treatment satisfaction questionnaire for medication (TSQM)
A 14-item questionnaire measuring a patient’s satisfac-
tion with medication. The time frame is 2–3 weeks, or
since the last medication use. Items are rated on a 5- or
7-point scale according to patients’ experience with the
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with side effects, ease of use and confidence [31].
Psychological general well-being (PGWB) index
A 22-item questionnaire measuring self-representations of
intrapersonal affective or emotional states reflecting a
sense of subjective well-being or distress during the past
month. The PGWB includes indicators of positive and
negative affective states. Questionnaire subscales are: anx-
iety, depressed mood, positive well-being, self control,
general health and vitality. Items are rated on a 6-point
scale, according to the intensity or frequency of the
affective experience. Total scores on the PGWB range
from 0 to 100 and are expressed as a summary score; a
higher score equals better quality of life. For each item,
the response option that indicates the greatest distress is
scored zero; the most positive option is scored five [32].
Statistical analysis
Validation strategy
Data was analyzed according to an a-priori statistical
analysis plan to determine item and factor structure, as-
sess internal and test-retest reliability, construct validity
using a nomological network approach, divergent and
convergent validity, discriminant validity, and to exam-
ine the minimally important difference. Validation ana-
lyses were conducted for the total COSI score as well as
for each (derived) domain score. All batteries and COSI
retests were double data entered into a centralized SPSS
database. All analyses were performed using SAS© (SAS
institute, Cary).
Item reduction and measurement model
The preliminary version of the COSI consisted of 42
core items with 6 additional items for working women,
assessing 4 core domains (Psychological, Interference in
Daily Life, Convenience and Side Effects) and 1domain
for Impact on Work Life. Items were rated on a 5-point
Likert scale which range from either “Not at all/Never”
to “Extremely/Always” with intervals (“rarely/a little”,
“sometimes/somewhat”, “often/a lot”).
Analytic guidelines of the decision criteria were used
to guide the process of item reduction of the preliminary
48 items. These included criteria for examination of
missing data (any items having 5% or greater missing
data were assessed for removal from the scale), ceiling
and floor effects (if the frequency of either response
extremes is greater than 50%, the item is considered to
be demonstrating a ceiling or floor effect), item-rest cor-
relations (Pearson’s correlation of .70 or greater is
acceptable) and item-to-item correlations (correlation
coefficients greater than 0.80 may indicate a redundancy be-
tween the items). Additionally, content validity (conceptual
relevance) of items was also considered in final decisionsas to whether or not an item should be deleted. This was
done to ensure that important patient reported key
concepts remained in the measure. Thus, final item reduc-
tion decisions were treated as an iterative process between
these psychometric methods and the conceptual frame-
work developed in the measure development process.
Factor analysis using VARIMAX rotation was performed
on the correlation matrices derived from the core items
comprising the COSI. In order to include all respondents,
work related items were not included in the factor ana-
lysis. The final solution for factors was also rotated using
oblique rotation (OBLIMIN) in order to establish the de-
gree of correlation between domains. The most appropri-
ate number of factors to be extracted was determined
using primarily (A) residual analysis, i.e., evaluation of the
ability of the factor solution to represent the correlation
structure, and (B) clinical and theoretical interpretability
of the solution. A scree plot of the principal component
solution was used as a guide to the number of factors that
were needed.
Reliability
Internal Consistency was assessed by Cronbach’s alpha
[33]. For scales or domains that are relatively unilateral,
reliability was expected to be high (>0.80); for scales or
domains that are more multifaceted, a lower reliability of
at least 0.70 was considered acceptable.
Test-retest reliability was analyzed for those subjects
who completed the re-test approximately 12 days after
completing the COS. Given that the women had expe-
rienced both oocyte retrieval and embryo transplant in
between administrations, it was expected that the re-
test would not only reveal the degree of error variation
that is a characteristic of the test, but would also be
sensitive to changes in perception of the original COSI
and thus, not be as strong a correlation as generally
expected for test-retest reliability.
Validity
In order to assess convergent validity, hypotheses re-
garding the relationship between the measure assessing
the similar concept to the COSI score were developed.
Pearson’s correlations were computed to measure the as-
sociation between the total and/or subscale scores on
the COSI measure for which the significant relationship
was expected.
In order to assess discriminate validity, hypotheses re-
garding the relationship between known groups and the
COSI score being tested were developed. The scores of
the groups on the COSI domains were compared using
descriptive statistics, and parametric tests, typically one-
way ANOVA with groups as a fixed factor (or a t-test in
case of two groups and appropriate contrasts comparing
groups when several groups were involved) to test for
Brod and Fennema Health and Quality of Life Outcomes 2013, 11:130 Page 5 of 10
http://www.hqlo.com/content/11/1/130significance between the known groups and the COSI
score. Table 1 presents the hypotheses for the tests of
validity.Exploratory analysis
The relationship between the COSI and other patient data
(e.g. age, ethnicity, cause of infertility), key treatment fac-
tors (e.g. number of injections), and the women’s relation-
ship to their fertility clinic (e.g. ease of contact) was
examined using regression analysis for continuous vari-
ables and one way ANOVA for categorical variables.Results
Sample description
The COSI validation sample consisted of 267 women
(United Kingdom: 80: Ireland: 45; United States: 142)
who completed the validation battery. The aggregate
sample had a mean age of 35.7 years. 85.0% of the par-
ticipants reported excellent or very good health. 79.4%
of the sample was self-identified as White/Caucasian.
The largest non-White/Caucasian group represented in
the sample was Asian-American/Pacific Islander (7.9%)
followed by mixed race (5.2%) or another ethnic group
not listed (4.1%), Latino/Hispanic (1.9%), and Black/
African American (1.5%). Additionally, a majority of
the sample was employed 30 or greater hours per week
(72.7%), and a majority earned equal to or greater than
$50,000 annually (92.1%) with over half of the sample
earning more than $100,000 annually (60.3%). 73.4% of
the sample had no children. The full demographic and
infertility factors description is shown in Table 2. On
average there were no marked differences in socio-
demographic factors across the three countries included.Item reduction and measurement model
Item reduction resulted in a final 28-item COSI. Four fac-
tors were identified: Interference in Daily Life (with 2
subdomains of Work and Home), Injection Burden, Psy-
chological Health and Compliance Worry. These domains
varied slightly from the a-priori hypothesized domains,
which also included Side Effects and a separate domain
for Work Interference, and did not include Injection
Worry. As a result, the a-priori concurrent and known-
groups validity hypotheses for the Side Effects domain
were not tested, and post-hoc hypotheses for the new
Compliance Worry were formulated based. A-priori hy-
potheses for the Work Interference domain were used to
support the Work Interference subdomain of the Daily
Life Interference domain. Incomplete data was minimal
and did not affect item reduction.
The final factor structure of the core COSI items
(excluding work items) is shown in Table 3.Reliability
Cronbach Alpha’s for the internal consistency of all
domains, and the total score were between 0.80 to 0.92
thus meeting the criteria of acceptable internal con-
sistency. Test–retest correlations were also acceptable
(between 0.72 to 0.87) for all domains and the total
score. Reliability ICC statistics on the COSI are shown
in Table 4.
Validity
All a-priori hypotheses for convergent and discriminant val-
idity were met. Additionally, the post-hoc convergent validity
hypotheses for the Injection Burden domain were also met.
Final measure
The final COSI consists of 28 items in 4 domains (Inter-
ference in Daily Life: Home 5 items, Work 4 items; Psy-
chological Health: 10 items; Injection Burden: 4 items;
Compliance Worry: 5 items).
The conceptual framework of items per domain of the
COSI is as shown in Figure 1.
Exploratory analyses
There was no significant relationship between COSI
Total score or any domains and major demographic fac-
tors: age, marital status, ethnicity (with exception of In-
jection Burden: p = 0.007, higher impact for Asian and
mixed race), employment status, education, treatment
protocol (with exception of Interference in Daily Life -
Work: p = 0.019, lower impact for agonist and antagonist
short flare-up protocols), income (with exception of
Interference in Daily Life: p = 0.024, higher impact for
income above $100.000) or previous injection experi-
ence. The overall impact of COS was lower (COSI total
score: p = 0.025) as well as the Interference in Daily Life
(home: p = 0.005 work p = 0.037) and Injection Burden
(p = 0.031) for those who were paying either all or some
of the costs of IVF themselves.
With regard to treatment factors, women who felt they
were better trained to self administer injections also had
lower overall impact (p = 0.002) as well as lower Interfer-
ence in Daily Life (home: p = 0.002, work: p = 0.05) and In-
jection Burden (p = 0.032). Also, women who injected
themselves reported lower Injection Burden then when
this was done by the husband or shared (p = 0.002). Fur-
ther, women reported lower overall impact (p = 0.013),
Psychological Impact (p = 0.047), Interference in Daily Life
at home (p = 0.04), and less Injection Burden (p = 0.017)
when the cause of infertility was related to a male factor.
Women who had a greater number of injections had
greater Injection Burden (p = 0.009), and depending on
the number of monitoring visits (categorized as ≤3, 4–6,
7–9, ≥10) did not experience equal Overall Impact (p <
0.001), Psychological Impact (p = 0.002), Interference in
Table 2 Demographic and infertility factors
Country
UK (N = 80) Ireland (N = 45) US (N = 142) Total (N = 267)
Age (years) at COSI date
N 79 45 141 265
Mean (SD) 36.3 (4.0) 35.9 (3.7) 35.2 (4.7) 35.7 (4.4)
General health, n (%)
Excellent/Very good 69 (86.3) 38 (84.4) 120 (84.5) 227 (85.0)
Good 10 (12.5) 7 (15.6) 21 (14.8) 38 (14.2)
Fair 1 (1.3) 0 0 1 (0.4)
Missing 0 0 1 (0.7) 1 (0.4)
Employment status, n (%)
Employed - 30 or more hours/Week 57 (71.3) 30 (66.7) 107 (75.4) 194 (72.7)
Employed - less than 29 hours/Week 14 (17.5) 9 (20.0) 15 (10.6) 38 (14.2)
Unemployed (seeking employment) 3 (3.8) 2 (4.4) 3 (2.1) 8 (3.0)
Not seeking employment (homemaker, retired, etc.) 6 (7.5) 4 (8.9) 16 (11.3) 26 (9.7)
Missing 0 0 1 (0.7) 1 (0.4)
Highest level of education, n (%)
Grade school (elementary) or less or Secondary school or technical school
(some coursework or graduated)
7 (8.8) 12 (26.7) 9 (6.3) 28 (10.5)
College or further education or Higher education (completed graduation) 43 (53.8) 23 (51.1) 89 (62.7) 155 (58.1)
Post graduate studies 30 (37.5) 10 (22.2) 44 (31.0) 84 (31.5)
Annual household income, n (%)
Less than £10 OR less than $19,900 1 (1.3) 0 2 (1.4) 3 (1.1)
£10 - £25,999 OR $20,000–$49,999 5 (6.3) 4 (8.9) 7 (4.9) 16 (6.0)
£25 - £50,999 OR $50,000–$99,999 26 (32.5) 14 (31.1) 45 (31.7) 85 (31.8)
More than £51,000 OR more than $100,000 47 (58.8) 27 (60.0) 87 (61.3) 161 (60.3)
Missing 1 (1.3) 0 1 (0.7) 2 (0.7)
Number of other living children, n (%)
0 67 (83.8) 28 (62.2) 101 (71.1) 196 (73.4)
1 or more 12 (15.0) 14 (31.1) 40 (28.2) 66 (24.7)
Missing 1 (1.3) 3 (6.7) 1 (0.7) 5 (1.9)
IVF treatment payment, n (%)
Self 59 (73.8) 41 (91.1) 56 (39.4) 156 (58.4)
Insurance/NHS 21 (26.3) 2 (4.4) 41 (28.9) 64 (24.0)
Combination self and insurance 0 1 (2.2) 40 (28.2) 41 (15.4)
Other 0 1 (2.2) 5 (3.5) 6 (2.2)
Cause infertility, n (%)
Male factor 31 (38.8) 19 (42.2) 59 (41.5) 109 (40.8)
Tubal factor 15 (18.8) 4 (8.9) 21 (14.8) 40 (15.0)
Endometriosis 10 (12.5) 5 (11.1) 10 (7.0) 25 (9.4)
Cervical mucus problems 1 (1.3) 0 1 (0.7) 2 (0.7)
Unexplained infertility 23 (28.8) 15 (33.3) 28 (19.7) 66 (24.7)
Missing or unknown 0 2 (4.4) 23 (16.2) 25 (9.4)
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Table 2 Demographic and infertility factors (Continued)
Duration of infertility, n (%)
<1 year 1 (1.3) 0 6 (4.2) 7 (2.6)
1- ≤2 years 14 (17.5) 11 (24.4) 55 (38.7) 80 (30.0)
2- ≤4 years 33 (41.3) 17 (37.8) 36 (25.4) 86 (32.2)
Over 4 years 27 (33.8) 14 (31.1) 32 (22.5) 73 (27.3)
Missing 5 (6.3) 3 (6.7) 13 (9.2) 21 (7.9)
COSI Controlled ovarian stimulation impact measure, IVF In vitro fertilization, NHS National health service, PCOS Polycystic ovarian syndrome, AMA Advanced
maternal age.
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0.044), with categories corresponding to lower number of
visits corresponding to improved scores.
The relationship the women had with their fertility clinic





Feel emotional ups and downs 73
Feel emotionally exhausted 73
Feel anxious 66
Feel depressed 63
Feel strain or tension in relationship 54
Feel not able to manage life 49
Feel good about self* 47
Feel physically exhausted 47
Bothered: side effects from the med. 46
Worry: taking the correct dose 84
Worry: injecting properly 80
Worry: missing a dose 66
Worry: medication at the right time 27 64
Problem: learn how to take properly 45
Problem: manage or schedule time 25 21
Problem: keep up family/soc. life 35
Problem: travel or short trips
Convenient take meds at corr. time*
Problem: schedule monitoring visits 24
Bothered: injections 22
Bothered: injections required 29
Bothered: having to inject myself 28
Bothered: problems injection site 32
† Excluding work-related questions, including imputed missing values.
* Variables have been mirrored for the analysis. Factor loadings have been multiplie
Factor loadings with an (absolute) value <0.2 were not printed.
The communality indicates the proportion of variance explained by the 4 factor sol
COSI Controlled ovarian stimulation impact measure.who felt they had a better relationship with their clinics,
or that the clinics were easy to contact and had fewer
monitoring visits, had significantly better outcomes in
both overall impact as well as for most domains. Addition-
ally, significant relationships (p < 0.001) were foundlution and Varimax rotation†
Factor Communality
3 4



























Table 4 Reliability ICC statistics on the COSI
Scale identification Reliability* Test-retest reliability
COSI Total 0.92 0.87
Interference in Daily Life
Work 0.80 0.80
Home 0.80 0.72
Compliance Worry 0.84 0.78
Psychological Health 0.87 0.82
Injection Burden 0.84 0.83
*Reliability based on internal consistency using Cronbach’s alpha.
COSI Controlled ovarian stimulation impact measure.
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women felt the infertility treatment was, the degree of
supportiveness of spouse and friends and family, their
need to rearrange work schedule and the degree of sup-
portiveness and ease of contacting their fertility clinic. Re-
garding the Daily Life Interference domain, women who
worked, and who needed to rearrange their work schedule
due to their COS treatment, did have greater Daily Life
Work Interference (p < 0.001), and women with a greater
number of monitoring visits had greater Daily Life Home
Interference (p < 0.001) and Daily Life Work Interference
if they worked (p = 0.003).Bothered: injections              
Bothered: injections required     
Bothered: having to inject myself 
Bothered: problems injection site
Feel stressed                          
Feel emotionally exhausted             
Feel emotional ups and downs           
Feel anxious                           
Feel depressed                         
Feel good about self                   
Feel not able to manage life           
Feel strain or tension in relationship 
Feel physically exhausted              
Bothered: side effects from the med.   
Worry: taking the correct dose      
Worry: injecting properly           
Worry: medication at the right time 
Worry: missing a dose               
Problem: learn how to take properly
Problem: manage or schedule time       
Problem: keep up family/soc. life      
Problem: travel or short trips         
Problem: schedule monitoring visits    
Convenient take meds at corr. time     
Difficult: continue your work schedule 
Difficult: be as productive as usual   
Difficult: be working                  
Difficult: concentrate on work     
Work
Home
Figure 1 Conceptual framework.Discussion
These findings suggest that the 28-item COSI can be con-
sidered a well-developed and valid PRO measure with
well-defined domains (Interference in Daily Life (with 2
subdomains of Work and Home), Injection Burden, Psy-
chological Health and Compliance Worry) which assess
the impact of COS on women’s functioning and well-
being. Further, each of these domains has been found to
be acceptable psychometrically and can be considered ap-
propriate for use as individual concepts. IVF has been
found to create anxiety in patients [21] and this anxiety
may be related to treatment outcomes [15-19]. Further,
discontinuation of fertility treatment has been attributed
to the burden of treatment [34]. It has been suggested that
further evaluation of the efficacy of treatments and inter-
ventions that reduce burden is needed [34]. The COSI has
been rigorously developed following the Guidance for in-
dustry: patient-reported outcome measures [22], as a
measure of the impact of COS on patient functioning and
well-being. This study has shown that the COSI is relevant
to patients, clinically meaningful, valid and reliable. As
such, the COSI should be helpful to clinicians to assess
the multiple impacts of COS and the effectiveness of inter-
ventions geared to reduce this anxiety.
The impact of a treatment can often be mitigated by
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treatment [21,35,36]. In this study, we also found, as
shown in the exploratory analyses that the impact of COS
on women is not insignificant and that this impact can be
mitigated by factors such as where the procedure is
conducted, the type of treatment, number of visits and in-
jections as well as family, clinic and work support struc-
tures. A greater focus on these factors by clinicians should
help to improve care and reduce the burden of infertility.
Some limitations and future considerations should be
mentioned. Unfortunately, due to ethics requirements,
we were not able to collect any information on women
who choose not to participate in the validation study,
thus the extent to which women who did participate
were similar to women who did not participate is un-
known. However, the characteristics of the women who
did participate appear to be representative of the gen-
eral population of women undergoing COS. Further, the
study was conducted in Western countries and the sam-
ple was limited in ethnic diversity. Although the ex-
ploratory analyses did not find an effect of ethnicity on
the impact of COS, future research is needed to confirm
this finding. The exploratory analyses also suggested
that site characteristics may impact outcomes and this
also should be an area for future research in order to
more clearly define site characteristics that help rather
than hinder women in coping with COS. Finally, as this
was a validation study, translation issues have not yet
been addressed. It will be important that any transla-
tions of the COSI take into consideration cultural
equivalency in the translation process.
Validation is an iterative process and should be continu-
ally ongoing as PRO measures are initially developed and
used in clinical practice. Further work on the COSI should
examine responsiveness and interpretability of the COSI
scores in future studies. Further, as this study was con-
ducted in western cultures, additional validation work in
non-western cultures would be warranted.Conclusions
The study findings suggest that the 28-item COSI can be
considered a well-developed and valid PRO measure
with well-defined domains which assess the impact of
COS on women’s functioning and well-being.Abbreviations
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